Reata Pharmaceuticals, Inc. - (RETA): Price and Financial Metrics

Reata Pharmaceuticals, Inc. - (RETA): $110.72

1.86 (+1.71%)

POWR Rating

Component Grades














  • Growth is the dimension where RETA ranks best; there it ranks ahead of 37.15% of US stocks.
  • RETA's strongest trending metric is Value; it's been moving up over the last 48 weeks.
  • RETA ranks lowest in Momentum; there it ranks in the 13th percentile.

RETA Stock Summary

  • For RETA, its debt to operating expenses ratio is greater than that reported by merely 0.49% of US equities we're observing.
  • With a price/sales ratio of 510.59, Reata Pharmaceuticals Inc has a higher such ratio than 98.77% of stocks in our set.
  • As for revenue growth, note that RETA's revenue has grown -49.42% over the past 12 months; that beats the revenue growth of only 4.9% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to Reata Pharmaceuticals Inc, a group of peers worth examining would be IONS, ACRS, CUE, AKTS, and XBIT.
  • Visit RETA's SEC page to see the company's official filings. To visit the company's web site, go to

RETA Valuation Summary

  • In comparison to the median Healthcare stock, RETA's EV/EBIT ratio is 147.78% lower, now standing at -14.
  • Over the past 64 months, RETA's price/sales ratio has gone up 494.4.
  • RETA's price/earnings ratio has moved up 166 over the prior 64 months.

Below are key valuation metrics over time for RETA.

Stock Date P/S P/B P/E EV/EBIT
RETA 2021-08-31 499.6 12.3 -14.3 -14.0
RETA 2021-08-30 496.4 12.3 -14.2 -13.9
RETA 2021-08-27 507.7 12.6 -14.5 -14.2
RETA 2021-08-26 489.1 12.1 -14.0 -13.6
RETA 2021-08-25 505.8 12.5 -14.5 -14.2
RETA 2021-08-24 496.6 12.3 -14.2 -13.9

RETA's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • RETA has a Quality Grade of C, ranking ahead of 32.03% of graded US stocks.
  • RETA's asset turnover comes in at 0.01 -- ranking 389th of 677 Pharmaceutical Products stocks.
  • SUPN, LUMO, and PTCT are the stocks whose asset turnover ratios are most correlated with RETA.

The table below shows RETA's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.010 1 3.336
2021-03-31 0.012 1 4.920
2020-12-31 0.013 1 8.823
2020-09-30 0.013 1 34.641
2020-06-30 0.027 1 271.349
2020-03-31 0.042 1 -40.289

RETA Price Target

For more insight on analysts targets of RETA, see our RETA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $226.44 Average Broker Recommendation 1.17 (Strong Buy)

RETA Stock Price Chart Interactive Chart >

Price chart for RETA

RETA Price/Volume Stats

Current price $110.72 52-week high $186.82
Prev. close $108.86 52-week low $76.34
Day low $108.69 Volume 176,416
Day high $112.75 Avg. volume 351,399
50-day MA $114.67 Dividend yield N/A
200-day MA $116.48 Market Cap 4.03B

Reata Pharmaceuticals, Inc. - (RETA) Company Bio

Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on identifying, developing, and commercializing product candidates that modulate the activity of key regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with various serious or life-threatening diseases. The company was founded in 2002 and is based in Irving, Texas.

RETA Latest News Stream

Event/Time News Detail
Loading, please wait...

RETA Latest Social Stream

Loading social stream, please wait...

View Full RETA Social Stream

Latest RETA News From Around the Web

Below are the latest news stories about Reata Pharmaceuticals Inc that investors may wish to consider to help them evaluate RETA as an investment opportunity.

2 Biotech Stocks to Buy Right Now

Biotech stocks can be highly risky. In this Motley Fool Live video recorded on Sept. 8, 2021, Motley Fool contributors Keith Speights and Brian Orelli talk about two biotech stocks to buy right now that offer attractive risk-reward propositions. Keith Speights: Brian, I'm going to pitch you a softball here.

Yahoo | September 19, 2021

Why Is Reata Pharmaceuticals, Inc. (RETA) Up 12.2% Since Last Earnings Report?

Reata Pharmaceuticals, Inc. (RETA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo | September 8, 2021

Stanley Druckenmiller is Selling These 12 Stocks

In this article, we discuss the 12 stocks Stanley Druckenmiller is selling. If you want to skip our detailed analysis of these stocks, go directly to the Stanley Druckenmiller is Selling These 5 Stocks. Stanley Druckenmiller, the chief of New York-based Duquesne Capital, is a titan of the investing world with an impressive investing history […]

Yahoo | August 24, 2021

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reata Pharmaceuticals, Inc. - RETA

New York, New York--(Newsfile Corp. - August 17, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Reata Pharmaceuticals, Inc. ("Reata" or the "Company") (NASDAQ: RETA). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.The investigation concerns whether Reata and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about ...

Yahoo | August 17, 2021

Why Reata Pharmaceuticals Stock Is Diving Today Despite Q2 Beats

Reata Pharmaceuticals (NASDAQ: RETA) was having a terrible Tuesday, with its stock trading down by nearly 17% in late afternoon action. This doesn't necessarily mean the end of bardoxolone; Reata believes that "each of the identified issues is addressable with additional data and analyses."

Yahoo | August 10, 2021

Read More 'RETA' Stories Here

RETA Price Returns

1-mo 4.58%
3-mo -26.16%
6-mo 13.38%
1-year 1.94%
3-year 21.63%
5-year 379.31%
YTD -10.44%
2020 -39.53%
2019 264.40%
2018 98.09%
2017 29.73%
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.963 seconds.